Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H24O7S |
Molecular Weight | 408.465 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCO[C@@H](CC1=CC=C(OCCC2=CC=C(OS(C)(=O)=O)C=C2)C=C1)C(O)=O
InChI
InChIKey=CXGTZJYQWSUFET-IBGZPJMESA-N
InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1
Molecular Formula | C20H24O7S |
Molecular Weight | 408.465 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:24:21 UTC 2023
by
admin
on
Fri Dec 15 16:24:21 UTC 2023
|
Record UNII |
6734037O3L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98233
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8092
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | |||
|
m1262
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | Merck Index | ||
|
DTXSID4048773
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | |||
|
C75985
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | |||
|
6734037O3L
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | |||
|
C501413
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | |||
|
TESAGLITAZAR
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | |||
|
251565-85-2
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | |||
|
DB06536
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | |||
|
208901
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | |||
|
QQ-51
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | |||
|
100000089231
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | |||
|
SUB25217
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY | |||
|
CHEMBL282686
Created by
admin on Fri Dec 15 16:24:21 UTC 2023 , Edited by admin on Fri Dec 15 16:24:21 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
EXCRETED UNCHANGED |
URINE
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST |
Tesaglitazar is a novel dual-acting peroxisome proliferator-activated receptor alpha and gamma agonist.
|
||
|
TARGET -> AGONIST |
Tesaglitazar is a novel dual-acting peroxisome proliferator-activated receptor alpha and gamma agonist.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||